SN 29900

SN 29900 is a tetra-fluorinated small molecule analog of N-(o-carboxybenzoyl)glutamic acid imide (CGI), which is an active hydrolysis metabolite of thalidomide. Developed by researchers at the University of Auckland, SN 29900 functions as an angiogenesis inhibitor and an immunomodulatory agent. Preclinical evaluations have shown that SN 29900 is significantly more potent than CGI, demonstrating a 17-fold increase in the inhibition of endothelial cell tube formation and effective suppression of lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) production in myeloma cells. While it exhibits improved chemical stability at low pH compared to its parent metabolite, its pharmacokinetic profile in murine models indicates more rapid clearance than lenalidomide. It has been investigated for its potential therapeutic application in multiple myeloma and other cancers where angiogenesis and cytokine production are key drivers of disease progression.

Other names

tetra-fluorinated analog of N-(o-carboxybenzoyl)glutamic acid imide